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DEPRESSION IN 
PRIMARY CARE
…with a focus on first-line medications
Michael Danielewicz, MD
August 6, 2020
This lecture will cover
■ An overview of selective serotonin reuptake inhibitors (SSRIs), serotonin-
norepinephrine reuptake inhibitors (SNRIs), bupropion and mirtazapine
■ Appropriate selection and dose adjustments of first-line agents for depressive 
disorders in a primary care setting
■ Monitoring and tapering first-line antidepressants
■ Special considerations in treatment
■ Future directions for antidepressant treatment
This lecture will not cover
■ In-depth initial diagnosis of different depressive disorders
■ In-depth uses of antidepressants for conditions other than depression
■ Medications other than SSRIs, SNRIs, mirtazapine, and bupropion
■ Suggested adjunctive treatments to medication therapy 
PRIMARY CARE OR 
PSYCHIATRY?
“It is often assumed that depressed patients in primary care settings 
are less severely depressed, have a milder course of illness, and are 
more likely to present with fatigue or other somatic symptoms 
compared to patients at psychiatry clinics.  However, there were few 
differences in demographics or symptom profiles between primary care 
and psychiatric clinic patients…”
- Kennedy, 2013
A framework for 
approaching 
depression
Flowchart courtesy Ng et al.
MECHANISMS OF 
ACTION (IN BRIEF)
SSRI
SNRI
Mirtazapine is a bit harder to diagram…
■ “Atypical” antidepressant
■ Antagonizes central presynaptic alpha2-adrenergic receptors, increasing release of 
serotonin and norepinephrine
■ Also antagonizes H1 histamine receptors (sedation/calming) and H-HT2A, 5-HT2C, 
and 5-HT3 serotonin receptors
– Serotonin then interacts with the 5-HT1 receptor, leading to antidepressant 
effects
Bupropion
■ Norepinephrine/dopamine reuptake inhibitor (NRDI)
■ Weakly inhibits enzymes that are involved in reuptake of norepinephrine and 
dopamine in synaptic cleft
SELECTING A 
MEDICATION
Where to start
■ Much of the selection of a first-line antidepressant is based off:
– The patient’s story
– Side effect profile
■ Evidence on “best” first-line options is somewhat limited
– Often difficult to assess given differential responses to drugs
– Significant publication bias
■ 2008 study by Turner et al. examined 74 studies, found that 97% of those with 
positive findings were published, but those with negative findings were either not 
published or published to portray some positive finding
General class considerations: SSRIs
■ Common side effects:
– QTc prolongation
– Sexual dysfunction
– GI upset
■ There is an increased risk of GI bleeding with SSRI use, especially in patients on 
antiplatelet, anticoagulation, and NSAIDs
■ Hyponatremia is a risk, generally in older adults
■ Dose adjustments are generally necessary for patients with liver disease
■ Geriatric dosing: “start low and go slow” – generally consider 50% dose reduction
Case 1
SH is a 30 year old nurse with no significant past medical history.  He 
presents to your clinic with complaints of depressed mood and 
anhedonia.  He is “incredibly fatigued” and can barely get through a day 
at work.  You diagnose major depression.  What might be a good first 
choice antidepressant for SH?
Fluoxetine
■ Most activating SSRI
■ Longest half-life of any SSRI (7-15 
days)
■ Potent CYP inhibitor (mostly 2D6) –
use with caution in medically 
complex individuals
■ Adult dosing: start at 20mg daily, 
can up-titrate in a few weeks to 
maximum 80mg daily
Fluoxetine
■ Good choice for:
– Patients who might forget to take medications every day
– Patients who do not take many other medications
– Patients who complain of excessive fatigue
■ Less ideal for:
– Patients who may not fare well with initial activation
– Patients on beta blockers, antiarrhythmics, calcium channel blockers, warfarin, 
traditional antipsychotics, and certain benzodiazepines
– Older patients 
– Patients with severe liver disease
Case 2
HD is a 75 year old female with a history of a-fib on warfarin, HFrEF (EF 
45%), hypertension, and hyperlipidemia.  She has been attempting to 
undergo talk therapy for depression, but is now willing to try a 
medication.  What might be her best options?
Citalopram and escitalopram
■ Mildly sedating (c), neither sedating 
nor activating (e)
■ Half life: 27-32h (e), 36h (c)
■ Minimal CYP inhibition
■ Adult dosing:
– C: 20mg starting dose, may 
increase in no less than one 
week to max 40mg 
– E: 10mg starting dose, may 
increase in no less than one 
week to max 20mg
Citalopram and escitalopram
■ Good choice for:
– Older adults
– Adults with complex medical issues on medications metabolized by CYP450 
enzymes
– Patients with GI sensitivity (e)
■ Less ideal for:
– Patients with excessive fatigue/apathy as a presenting symptom 
– Patients with severe renal disease (CrCl <20)
■ Partially renally excreted
Case 3
VC is a 55 year old male with a history of hypertension, hyperlipidemia, 
and asthma presenting to clinic for a routine physical exam.  In the 
process, his PHQ-9 reveals a score of 15 and he reveals he has had low 
energy and his mood is down.  He feels as though he is moving slowly 
lately.  Which might be a good first-choice medication for him?
Sertraline
■ Tends to be activating
■ Half-life: 22-36 hours
■ Minimal CYP inhibition
■ Adult dosing: 50mg starting dose, 
may increase in 25mg increments 
weekly, max dose 200mg daily
Sertraline
■ Good choice for:
– Patients with medical issues; those on other drugs
– Patients who might benefit from activation
– Patients who might benefit from the wide dose range
■ Less ideal for:
– Patients who may not fare well with initial activation
Case 4
JK is a 31 year old G1P0 currently at 9 weeks.  During her initial 
prenatal visit, you note that she has a history of major depression on 
paroxetine, as well as mild intermittent asthma on PRN symbicort.  She 
asks if either of these medications are problematic for her pregnancy.  
What do you tell her?
Paroxetine
■ Tends to be more sedating (and 
constipating) – higher 
anticholinergic activity
■ Half life: 21-24h
■ Potent CYP inhibition (especially 
2D6)
■ More anticholinergic activity at 
higher doses
■ Adult dosing: starting dose 20mg 
daily, may increase in 10mg 
increments weekly, max dose 50mg
Paroxetine
■ Good choice for:
– Patients who may not do well with initial insomnia/activation
■ Less ideal for:
– Patients on beta blockers, antiarrhythmics, calcium channel blockers, warfarin, 
traditional antipsychotics, and certain benzodiazepines
– Older patients (especially at higher doses)
– Patients who are overweight/obese
– Pregnant patients (risk of birth defects?)
– Patients who might require higher doses 
General class considerations: SNRIs
■ Common side effects:
– Overall similar to SSRIs
– Sometimes more nausea
– Dose dependent blood pressure increases (especially diastolic)
Case 5
AU is a 59 year old largely healthy female with a known diagnosis of 
MDD, previously treated with fluoxetine.  She self-discontinued the 
medication as she did not feel it was working.  She comes to the office 
today noting significant hot flashes and vaginal dryness, consistent with 
menopause.  She would also like to discuss her mood symptoms, which 
have worsened recently.  What antidepressant might be a good choice?
Venlafaxine
■ Can have some activation at higher doses
■ Very short half-life (3—7 hours, 9-13 for 
active metabolite
■ Adult dosing: 
– IR:  starting dose 75mg/day dosed 
q8h-q12h, may increase in 75mg 
increments after no less than four 
days to max  ~375mg/day
– ER: starting dose 37.5-75mg daily, 
may increase in 75mg increments 
after no less than four days to max 
~225mg/day
■ Dose reductions required in hepatic/renal 
impairment (50% and 25% respectively)
Venlafaxine
■ Good choice for:
– Patients who have not had success with other SSRIs
– Patients who also have menopausal vasomotor symptoms
■ Less ideal for:
– Patients with hypertension
– Patients at risk for abrupt discontinuation of therapy
– Patients with significant GI disturbance at baseline
Case 6
AL is a 71 year old male with metastatic prostate cancer.  Recently, he 
states that his mood has been down as he has learned his cancer is 
worsening.  He has lost 15 pounds over the past 6 months.  He reports 
that he is anxious and restless.  What might be a good antidepressant 
option for AL?
Mirtazapine
■ Induces sleep (at lower doses)
■ Weight gain common
■ Can be helpful for nausea
■ Half life: 20-40h
■ No significant CYP interactions
■ Dosing:
– For sleep – 7.5 mg nightly
– Depression – 15 mg starting 
dose, increase in 15mg 
increments q1-2 weeks, max 
dose 45mg
Mirtazapine
■ Good choice for:
– Patients having difficulty sleeping or poor appetite
– Patients with cancer
■ Less ideal for:
– Patients with excessive fatigue
– Patients who are overweight or would not benefit from weight gain
– Patients with neutropenia
Case 7
SH from Case 1, the 30 year old healthy male, returns to the office.  He 
was hopeful the fluoxetine would help, but couldn’t tolerate the sexual 
side effects and self-discontinued it.  He is unwilling to restart any 
medication that might cause the same effects.  His mood is still down 
and his energy levels low.  What can you offer him?
Bupropion
■ Most activating antidepressant
■ Lowers seizure threshold
■ Low risk of sexual dysfunction
■ Half-life: 12-30 hours
■ Concern for CYP inhibition (2D6)
■ Three forms of bupropion available:
– Immediate release (~TID)
– Sustained release (BID)
– XL (daily)
Bupropion
■ Dosing varies by formulation:
– IR: starting dose 100mg q12h, can increase to q8h after four days.  If no 
improvement within several weeks, can increase to 150mg q8h.
– SR: starting dose 150mg daily, can increase to q12h after three days.  If no 
improvement, can increase to 200mg q12h after four weeks
– XL: starting dose 150mg PO daily, can increase to 300mg daily after four days.  
If no improvement, can increase to 450mg after four weeks
■ Some psychiatrists choose not to increase beyond 300mg daily
Bupropion
■ Good choice for:
– Patients who can’t tolerate sexual side effects of SSRIs
– Depressed patients with bipolar disorder (less likely to switch to mania)
– Patients with low energy
– Patients who are actively smoking
■ Less ideal for:
– Patients with a contraindication to use: seizure disorder, history of head 
trauma, and eating disorders
– Anxious patients who would not tolerate significant activation 
Is one antidepressant more effective?
– 2018 meta analysis in The Lancet
– Weighed efficacy in treating depression vs. acceptability to patients
– Found all antidepressants superior to placebo
– Escitalopram, mirtazapine, paroxetine, sertraline found to have “relatively 
higher response and lower dropout” than other antidepressants
The caveat…
“Our assessment overall found few differences between 
antidepressants when all data were considered, while there was 
more diversity in the range of efficacy and dropout patterns 
seen across the head-to-head comparisons than the meta-
analysis of antidepressants versus placebo.”
Summary: selecting an antidepressant
■ As of now, there is not a single “best” option
■ Selection driven by patient and their symptoms
■ Must consider certain factors when choosing a medication
– Activation vs. sedation
– Drug interactions
– Side effects
■ A wide range of options currently exist
– …including some not covered in this talk (duloxetine, desvenlafaxine, etc.)
MONITORING, 
DISCONTINUING, 
AND TAPERING 
MEDICATIONS
Monitoring efficacy
■ Generally, should wait at least four weeks after starting an antidepressant to assess 
– …and, realistically, as long as two months
■ Should monitor symptoms with some objective measure
– e.g. PHQ-9 
■ May need to titrate dose up to achieve response
■ Must also account for patient perceptions of efficacy
■ If an SSRI fails to improve mood, can try another.  If this fails, may try SNRI or 
alternative option.
Addressing side effects
■ Sexual side effects are very common with SSRIs
– May switch agents or consider augmentation with bupropion or mirtazapine
– For male sexual dysfunction, can also consider sildenafil
■ May be necessary to switch within drug classes to improve side effects (e.g. 
activation/sedation)
Duration of therapy
■ Current guidelines suggest four to twelve months for an initial episode of depression
■ Risk factors for relapse can help guide longer durations:
– Recurrent depression
– Other psychiatric illness
– Persistent symptoms
– Presence of other medical illness
■ ~60 percent of Americans on antidepressants have been taking for > two years
– …and ~14 percent have been on them for > 10!
Avoiding FInISH: tapering 
antidepressants
■ Abrupt discontinuation can lead to discontinuation syndrome
– FInISH: Flu-like symptoms, Insomnia, Imbalance, Sensory disturbances, 
hyperarousal
■ Shorter half-lives (venlafaxine) and paroxetine are especially prone to this syndrome
■ Fluoxetine has a long half-life and tapering is less of a concern
■ Depending on the antidepressant, may be beneficial to taper “old” agent while 
switching to the “new” one
Summary: monitoring
■ Antidepressants should be given ~two months for full efficacy
■ Up-titrating may be necessary
■ Ideal therapy duration for first occurrence is ~one year, but many people require 
longer
■ Tapering medications can help avoid discontinuation syndrome
SPECIAL 
CONSIDERATIONS
Serotonin Syndrome
■ Serotonin “overload”
– Agitation, tremors, hyperreflexia, hypertension, vomiting, 
arrhythmias, etc.
■ To avoid:
– Monitor the list at right and avoid too many combinations
– Take special caution with fluoxetine!
■ Its metabolite can persist for up to 2.5 weeks
Breastfeeding and antidepressants
■ Most antidepressants are transferred to breastmilk in low concentrations
– Fluoxetine and venlafaxine highest in infant serum samples
■ May find some level of discontinuation syndrome (irritability) 
■ Little evidence to support true adverse events
Antidepressants in adolescents
■ Fluoxetine is approved for depression in children 8 years of age or older, 
escitalopram in those 12 or older
■ Better outcomes when medications combined with talk therapy
■ FDA black box warning for SI in pediatric/adolescent patients, but no evidence of 
increased rates of completed suicide
When to refer to psychiatry
■ Treatment-resistant depression
■ Difficult cross-tapering
■ Medical complexity with multiple drug interactions
THE FUTURE OF 
ANTIDEPRESSANTS
Genetic testing: a panacea?
■ Specific genes have been associated with MDD
■ Current research has focused on identifying specific genetic variants that predict 
responses to antidepressants
The current state of affairs…
“[A]t present, there are insufficient data to support the 
widespread use of combinatorial pharmacogenetic testing in 
clinical practice, although there are clinical situations in which 
the technology may be informative, particularly in predicting 
side effects.
Summary: overall
■ Treating with first-line antidepressants is within the scope of practice of family 
medicine physicians
■ A wide range of medication options exist, and treatment is patient-directed
■ Careful monitoring for side effects and efficacy is critical
■ Tapering should be considered at time of discontinuation of therapy
■ The future of antidepressant therapy may be individualized medicine
Questions?
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